Insider Selling: Arcus Biosciences (NYSE:RCUS) President Sells 44,950 Shares of Stock

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 44,950 shares of the business’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $20.31, for a total transaction of $912,934.50. Following the sale, the president owned 1,042,110 shares of the company’s stock, valued at $21,165,254.10. This trade represents a 4.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link.

Arcus Biosciences Stock Up 0.3%

Shares of Arcus Biosciences stock traded up $0.06 during trading hours on Wednesday, reaching $20.25. The company’s stock had a trading volume of 1,141,207 shares, compared to its average volume of 1,097,460. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65. The stock’s fifty day simple moving average is $16.08 and its two-hundred day simple moving average is $11.75. The company has a market capitalization of $2.19 billion, a P/E ratio of -5.89 and a beta of 0.90. Arcus Biosciences, Inc. has a one year low of $6.50 and a one year high of $22.11.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share for the quarter, beating the consensus estimate of ($1.33) by $0.06. The business had revenue of $26.00 million for the quarter, compared to analysts’ expectations of $19.89 million. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The firm’s revenue for the quarter was down 45.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.00) EPS. On average, research analysts forecast that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

Institutional Trading of Arcus Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Amalgamated Bank lifted its stake in shares of Arcus Biosciences by 3.9% during the third quarter. Amalgamated Bank now owns 19,533 shares of the company’s stock worth $266,000 after buying an additional 736 shares during the period. Creative Planning lifted its position in Arcus Biosciences by 2.7% during the 3rd quarter. Creative Planning now owns 29,629 shares of the company’s stock worth $403,000 after acquiring an additional 771 shares during the period. GAMMA Investing LLC lifted its position in Arcus Biosciences by 59.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock worth $37,000 after acquiring an additional 1,021 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in Arcus Biosciences by 8.0% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,398 shares of the company’s stock valued at $142,000 after purchasing an additional 1,294 shares during the last quarter. Finally, Parallel Advisors LLC increased its holdings in shares of Arcus Biosciences by 1.6% in the second quarter. Parallel Advisors LLC now owns 88,007 shares of the company’s stock valued at $716,000 after purchasing an additional 1,422 shares during the period. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on RCUS shares. The Goldman Sachs Group upped their price target on Arcus Biosciences from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Thursday, October 30th. Wells Fargo & Company upped their target price on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Monday, October 20th. HC Wainwright raised their price target on shares of Arcus Biosciences from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Truist Financial restated a “buy” rating and set a $39.00 price target (up from $32.00) on shares of Arcus Biosciences in a report on Tuesday, October 7th. Finally, Wedbush set a $35.00 price objective on shares of Arcus Biosciences and gave the company an “outperform” rating in a research note on Wednesday, October 29th. Seven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.44.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.